The druggable genome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The dataset adds high-quality structural models across a broad range of Gene Ontology (GO) terms36,37, including pharmaceutically relevant classes such as enzymes and membrane proteins38 (Fig. 1d).”
From Highly accurate protein structure prediction for the human proteome (2021) · cites this paper as [38]
In the citing paper
“Proteins have several additional advantages as they are most often the direct mediators of biological processes and form the vast majority of currently druggable targets in disease160.”
From Measuring biological age using omics data (2022) · cites this paper as [160]
In the citing paper
“Only around 20% of the human proteome is considered to be druggable with small-molecule antagonists.”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [2]
In the citing paper
“Although this has been a highly effective approach, it has left potential drug targets undrugged or underdrugged45.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [45]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760 · cited 1×
“identified 483 targets, and concluded that there could be 5,000–10,000 potential targets on the basis of an estimate of the number of disease-related gene”
BackgroundMetabolite profiling for plant functional genomics
Fiehn, O., Kopka, J., Dörmann, P., Altmann, T., Trethewey, R. N., & Willmitzer, L. (2000) · Nature Biotechnology · doi:10.1038/81137 · Cited by 2,127 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundComparative Genomics of the Eukaryotes
Rubin, G. M., Yandell, M. D., Wortman, J. R., Gabor, G. L., Miklos, Nelson, C. R., Hariharan, I. K., Fortini, M. E., Li, P. W., Apweiler, R., et al. (2000) · Science · doi:10.1126/science.287.5461.2204 · Cited by 1,698
Apweiler, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.37 · Cited by 1,079
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations
Raamsdonk, L. M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M. C., Berden, J. A., Brindle, K. M., Kell, D. B., Rowland, J. J., et al. (2001) · Nature Biotechnology · doi:10.1038/83496 · Cited by 1,005 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundTweeddale, H., Notley-McRobb, L., & Ferenci, T. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.19.5109-5116.1998 · Cited by 393 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
Background
Cited by
Items 1,001–1,029 of 1,029
Bucci, M., Goodman, C. M., & Sheppard, T. L. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.489 · Cited by 52
Which three-dimensional characteristics make efficient inhibitors of protein–protein interactions?
Kuenemann, M. A., Bourbon, L. M. L., Labbé, C. M., Villoutreix, B. O., & Sperandio, O. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500487q · Cited by 42
Bellail, A. C., Jin, H. R., Lo, H.-Y., Jung, S. H., Hamdouchi, C., Kim, D., Higgins, R. K., Blanck, M., le Sage, C., Cross, B. C. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1486 · Cited by 42
“12 of 17 DISCUSSION Small-molecule drug discovery has focused on binding site occupation and functional inhibition of targeted proteins, yet 80% of the human proteome is undruggable due to lack of active sites or binding pockets (56).”
Ebenezer, O., Comoglio, P., Wong, G. K.-S., & Tuszynski, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044019 · Cited by 39
“DLin-KC2-DMA 2,2-dilinoleyl-4dimethylaminoethyl[1,3]-dioxola e [57]”
BackgroundInfluentialRNA-based therapeutics to treat human fungal infections
Bruch, A., Kelani, A. A., & Blango, M. G. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2021.09.007 · Cited by 39
Lee, C. H., Alpert, B. O., Sankaranarayanan, P., & Alter, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030098 · Cited by 36
“The human gene TLK2, with homologs in the plant Arabidopsis thaliana but not in the yeast Saccharomyces cerevisiae, encodes for a multicellular organismsspecific serine/threonine protein kinase, a biochemically putative drug target [24], which activity is directly dependent on ongoing DNA replication [25].”
McCafferty, C. L., Pennington, E. L., Papoulas, O., Taylor, D. W., & Marcotte, E. M. (2023) · Communications Biology · doi:10.1038/s42003-023-04773-7 · Cited by 35
“Similarly, the addition of new protein structures has the potential to aid in the drug design of protein targets (20,21) and when combined with deep mutational scanning (22) can predict the effect of missense variants (8).”
BackgroundStefanescu, R., Stanciu, G. D., Luca, A., Paduraru, L., & Tamba, B.-I. (2020) · Biomolecules · doi:10.3390/biom10060870 · Cited by 35
Liu, L., Shi, S., Chen, X., & Peng, M. (2013) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.06.002 · Cited by 33
Lago, S. G., Tomasik, J., van Rees, G. F., Ramsey, J. M., Haenisch, F., Cooper, J. D., Broek, J. A., Suarez-Pinilla, P., Ruland, T., Auyeug, B., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0123-4 · Cited by 30
Fragmentation of Integral Membrane Proteins in the Gas Phase
Skinner, O. S., Catherman, A. D., Early, B. P., Thomas, P. M., Compton, P. D., & Kelleher, N. L. (2014) · Analytical Chemistry · doi:10.1021/ac500864w · Cited by 29
Elucidating the druggability of the human proteome with eFindSite
Kana, O., & Brylinski, M. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00197-w · Cited by 27
Xie, L., & Xie, L. (2023) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010974 · Cited by 26
“However, many of 45 disease-associated proteins neither have suitable binding pockets for small molecule drugs nor bind inhibitors 46 with considerable affinity [1].”
The impact of AI on modern oncology from early detection to personalized cancer treatment
Li, J., Zhang, L., Yu, Z., Bao, Z., Li, D., & Wang, L. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01276-6 · Cited by 24
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Lin, Y., Lin, H., Liu, Z., Wang, K., & Yan, Y. (2014) · Journal of Separation Science · doi:10.1002/jssc.201400569 · Cited by 23
Liu, X., Zhang, Y., Ward, L. D., Yan, Q., Bohnuud, T., Hernandez, R., Lao, S., Yuan, J., & Fan, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-95354-3 · Cited by 21
Benson, N., Matsuura, T., Smirnov, S., Demin, O., Jones, H. M., Dua, P., & van der Graaf, P. H. (2013) · Interface Focus · doi:10.1098/rsfs.2012.0071 · Cited by 20
“Such targets have been referred to as ‘druggable’ [15].”
BackgroundProtein–Protein Interaction Prediction for Targeted Protein Degradation
Orasch, O., Weber, N., Müller, M., Amanzadi, A., Gasbarri, C., & Trummer, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137033 · Cited by 17
Su, C.-Y., van der Graaf, A., Zhang, W., Jang, D.-K., Selber-Hnatiw, S., Yang, T.-Y., Butler-Laporte, G., Liang, K. Y. H., Matsuda, F., Costanzo, M. C., et al. (2024) · doi:10.1101/2024.10.17.24315553 · Cited by 17
Mu, X., Mu, C., Wang, M., Meng, C., Liu, H., & Lu, H. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s552644 · Cited by 16
Expression profiling of drug response - from genes to pathways
Herwig, R., & Lehrach, H. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.3/rherwig · Cited by 14
Dissecting the molecular basis for the modulation of neurotransmitter GPCR signaling by GINIP
Luebbers, A., Gonzalez-Hernandez, A. J., Zhou, M., Eyles, S. J., Levitz, J., & Garcia-Marcos, M. (2024) · Structure · doi:10.1016/j.str.2023.10.010 · Cited by 13
Dissecting the molecular basis for the modulation of neurotransmitter GPCR signaling by GINIP
(2023) · doi:10.1101/2023.04.20.537566 · Cited by 13
Tsou, L. K., Cheng, Y., & Cheng, Y.-C. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.04.004 · Cited by 10
“At present, about 70% of the approved small-molecule drugs are targeting enzyme active sites or G-protein coupled receptors [34].”
BackgroundProtein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy
Pham, A. C., Holstein, S. A., & Borgstahl, G. E. O. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0358 · Cited by 9
“Historically, competitive inhibitors which inhabit the substrate-binding pockets have remained a common mechanism of inhibition (60, 61).”
(2025) · doi:10.1073/pnas.2505710122 · Cited by 8
Kenakin, T. P. (2017) · Pharmacology in Drug Discovery and Development · doi:10.1016/b978-0-12-803752-2.00001-6 · Cited by 1
Metadata
- Authors
- Hopkins, A. L., & Groom, C. R.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Groom, Colin R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-09
- Volume
- 1
- Issue
- 9
- Pages
- 727-730
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074370114
- Cited by
- 3,305
- References
- 16
- Citations by year
- 2026: 91 · 2025: 113 · 2024: 131 · 2023: 116 · 2022: 155 · 2021: 150 · 2020: 144 · 2019: 147 · 2018: 136 · 2017: 132 · 2016: 144 · 2015: 182 · 2014: 162 · 2013: 161 · 2012: 212
- FWCI
- 70.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- druggable genome, therapeutic target, molecular targets, target identification
- MeSH terms
- Biological Availability, Chemistry, Pharmaceutical, Humans, Molecular Biology, Pharmacokinetics, Genome, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.